X-GEN Congress and Expo Features GenomeQuest Panel Session on Whole-Genome Diagnostics and Significance to Research

Share Article

Panel Discussion Offers Insight to Research Community from Experts in Sequencing, Pharma, IT, Diagnostic, and Payers

Globally, the world spends about $5T on health care and about 65% of therapy decisions are based on the results of diagnostics tests.

A panel discussion on whole genome sequencing and molecular diagnostics has been added to the 2011 X-Gen Congress. Remote Webcast is available through NGS Leaders, a new community created to advance the use and value of next-generation sequencing.

Panel Session Title:
Whole Genome Sequencing Applied to Clinical Diagnostics -- the Significance to the Research Community

Location:  X-Gen Congress and Expo, Hilton San Diego Resort, San Diego, CA

When: Friday, March 18, 2011 from 11:00am-11:50 am PST

Remote Webcast: NGS Leaders

Whole-genome sequencing applied to diagnostics holds great promise for health care. Globally, the world spends about $5T on health care and about 65% of therapy decisions are based on the results of diagnostics tests.

With the precipitous fall in the cost of sequencing, whole-genome sequencing may soon become practical – even common – for reporting on patient susceptibility, diagnosis, and treatment of genetic disorders. Benefits of this advance to medical professionals and patients include: higher precision, ability to detect complex/multi-gene conditions, far lower long-term costs for patients, economies of scale for instrument manufacturers, higher quality/repeatability for laboratories, and faster delivery/approval of research discoveries.

Included in this panel discussion is a demonstration of a newly released capability to analyze/report on a patient’s disease susceptibility, diagnosis, and treatment on over 2000 disorders from a single whole-genome sequence.

Topics and questions addressed by this panel:

  •     What research and technological developments will help drive this advance?
  •     How can we better integrate research and clinical efforts/data to accelerate "translation"?
  •     What does this mean for researchers and their organizations?
  •     What are the top research bottlenecks/concerns and what can be done to address them?

Panel Participants:

  •     Resnick Richard Resnick, CEO, GenomeQuest (Moderator)
  •     Eliot Shearer, University of Iowa Carver College of Medicine
  •     Francois Ferre, PhD, CEO andjavascript:void(0); President, AltheaDx
  •     Harry Glorikian, CEO, Scientia Advisors
  •     Michael Moradian, PhD, Molecular Diagnostics, Kaiser Permanente
  •     Greg Heath, PhD, Senior Vice President and General Manager, Diagnostics, Illumina
  •     Eric Glazer, Managing Director, NGS Leaders (Host)

Related Links:
GenomeQuest Advances Whole-Genome Sequencing to Clinical Diagnostics

Are You Ready for Whole Genomes in the Electronic Health Record?

Video: video available for replay after the panel.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Anthony Flynn
Visit website